Only additional point I'd like to make is that Aczone is an antibiotic and there are obviously concerns about its overuse and reduction of efficacy over time. However, as a treatment now it is effective and approved but funnily enough recently losing exclusivity its revenue has significantly reduced due to generic brand pressure.
I think this points to BTX 1503 still being a promising treatment with potential for acquisitions by larger pharma companies that would like new and novel products that can provide good returns.
I'd still love to get other peoples takes on my comments above and if any people know of other treatments that compete with BTX 1503.
Only additional point I'd like to make is that Aczone is an...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.020(4.94%) |
Mkt cap ! $702.9M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 38.5¢ | $1.331M | 3.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 1717037 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 327032 | 33 |
View Market Depth
| Last trade - 12.13pm 18/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |